Read More

Blindness-Focused LENZ Therapeutics’ Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a bright future with a Buy rating and $34 price target.

ABBV

Read More

Cartesian Therapeutics’ Rare Disease Candidate Shows Long Lasting Benefit Over Argenx’s Vyvgart, Analyst Initiates With Buy

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current standards. Analysts project substantial market capture and peak sales potential.

ARGX